The genomic diagnostics product developer secured $16.2m in a round led by Heda's healthcare investment arm, adding to a $9m series A in 2017.
Heavy equipment manufacturer Heda Group has led a RMB115m ($16.2m) series B round for China-based diagnostics technology developer Lc-Bio through an undisclosed healthcare investment vehicle, DealStreetAsia reported yesterday.
Junchuan Capital, Taimeng Investment, Sinowisdom, Zheshang Venture Capital and CrestValue Capital also participated in the round.
Lc-Bio provides diagnostic testing kits utilising genomic sequencing technology for conditions such as cancer, focusing on gene and protein analysis. The series B funds will go to the ongoing commercialisation of its DNA synthesis technology.
Zheshang…
